CIK 0000906709
- Non-accelerated filer
- Smaller reporting company
NEKTAR THERAPEUTICS
Sign in to watch- Ticker
- NKTR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 943134940
- Phone
- +1 415-482-5300
- Business address
- 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158
- Former names
- INHALE THERAPEUTIC SYSTEMS INC, INHALE THERAPEUTIC SYSTEMS
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-12-15 | Nicholson John SVP & Chief Operating Officer | Grant or award · Stock Option | +65,000 | 65,000 | ||
| 2017-12-15 | Labrucherie Gil M SVP & Chief Financial Officer | Grant or award | +26,000 | 103,216 | ||
| 2017-12-15 | Labrucherie Gil M SVP & Chief Financial Officer | Grant or award · Stock Option | +65,000 | 65,000 | ||
| 2017-12-15 | Hora Maninder SVP Pharma Dev & Mfg Ops | Grant or award | +15,000 | 83,136 | ||
| 2017-12-15 | Hora Maninder SVP Pharma Dev & Mfg Ops | Grant or award · Stock Option | +37,500 | 37,500 | ||
| 2017-12-15 | Doberstein Stephen K SVP & Chief Scientific Officer | Grant or award | +26,000 | 69,820 | ||
| 2017-12-15 | Doberstein Stephen K SVP & Chief Scientific Officer | Grant or award · Stock Option | +65,000 | 65,000 | ||
| 2017-12-13 | ROBIN HOWARD W President & CEO | Exercise or conversion | +83,333 | $11.34 | $945K | 272,768 |
| 2017-12-13 | ROBIN HOWARD W President & CEO | Sale | −83,333 | $55.69 | $4.6M | 189,435 |
| 2017-12-13 | ROBIN HOWARD W President & CEO | Exercise or conversion · Stock Option | −83,333 | 83,333 | ||
| 2017-11-16 | Thomsen Jillian B. SVP & Chief Accounting Officer | Returned to the company | −5,289 | $44.23 | $234K | 60,549 |
| 2017-11-16 | ROBIN HOWARD W President & CEO | Returned to the company | −18,069 | $44.23 | $799K | 189,435 |
| 2017-11-16 | Nicholson John SVP & Chief Operating Officer | Returned to the company | −6,620 | $44.23 | $293K | 246,536 |
| 2017-11-16 | Labrucherie Gil M SVP & Chief Financial Officer | Returned to the company | −6,698 | $44.23 | $296K | 76,716 |
| 2017-11-16 | Hora Maninder SVP Pharma Dev & Mfg Ops | Returned to the company | −5,597 | $44.23 | $248K | 67,636 |
| 2017-11-16 | Gergel Ivan P. SVP & Chief Medical Officer | Returned to the company | −5,022 | $44.23 | $222K | 56,553 |
| 2017-11-16 | Doberstein Stephen K SVP & Chief Scientific Officer | Returned to the company | −4,782 | $44.23 | $212K | 43,820 |
| 2017-11-15 | Thomsen Jillian B. SVP & Chief Accounting Officer | Grant or award | +15,000 | 65,838 | ||
| 2017-11-15 | Thomsen Jillian B. SVP & Chief Accounting Officer | Grant or award · Stock Option | +37,500 | 37,500 | ||
| 2017-11-15 | ROBIN HOWARD W President & CEO | Grant or award | +55,000 | 207,504 |
Page 37 of 43 · 847 trades